Table 4.
Prognostic factors associated with overall survival in the entire cohort.
| Variables | Category | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | p-Value | HR | 95% CI | p-Value | ||
| Age (years) | <75 | 1 | 0.242 | 1 | 0.044 | ||
| ≥75 | 1.182 | 0.893–1.566 | 1.355 | 1.008–1.820 | |||
| Sex | male | 1 | 0.756 | 1 | 0.467 | ||
| female | 0.942 | 0.647–1.372 | 0.865 | 0.586–1.278 | |||
| Etiology | viral | 1 | 0.250 | 1 | 0.532 | ||
| non-viral | 0.837 | 0.618–1.133 | 0.903 | 0.656–1.243 | |||
| Child–Pugh class | A | 1 | 0.401 | ||||
| B | 1.284 | 0.716–2.304 | |||||
| ALBI grade | 1 or 2a | 1 | <0.001 | 1 | <0.001 | ||
| 2b or 3 | 2.002 | 1.488–2.692 | 1.823 | 1.325–2.508 | |||
| BCLC grade | B | 1 | 0.078 | 1 | 0.431 | ||
| C | 1.283 | 0.972–1.694 | 0.801 | 0.461–1.392 | |||
| Maximum intrahepatic tumor size (cm) |
≥5 | 1 | 0.212 | 1 | 0.099 | ||
| <5 | 0.880 | 0.721–1.075 | 1.033 | 0.994–1.075 | |||
| Intrahepatic tumor number | ≤4 | 1 | <0.002 | 1 | <0.001 | ||
| ≥5 | 1.548 | 1.176–2.039 | 1.859 | 1.327–2.604 | |||
| Macrovascular invasion | absent | 1 | 0.002 | 1 | 0.079 | ||
| present | 1.628 | 1.197–2.214 | 1.504 | 0.953–2.37 | |||
| Extrahepatic metastasis | absent | 1 | 0.497 | 1 | 0.001 | ||
| present | 1.098 | 0.838–1.438 | 2.297 | 1.378–3.828 | |||
| AFP (ng/mL) | <400 | 1 | 0.001 | 1 | 0.001 | ||
| ≥400 | 1.615 | 1.225–2.129 | 1.622 | 1.216–2.164 | |||
| Number of systemic therapy lines | ≥3 | 1 | <0.0001 | 1 | <0.001 | ||
| ≤2 | 2.208 | 1438–3.389 | 2.776 | 1.751–4.402 | |||
| Therapeutic efficacy | OR (CR + PR) | 1 | <0.0001 | 1 | <0.001 | ||
| non-OR | 2.186 | 1.506–3.174 | 2.516 | 1.704–3.716 | |||
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; ALBI, albumin–bilirubin; BCLC, Barcelona Clinic Liver Cancer stage; AFP, alpha-fetoprotein; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; OR, objective response.